Choroidal Neovascularization - Pipeline Review, H2 2015

Published: Oct, 2015 | Pages: 95 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Choroidal Neovascularization - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Choroidal Neovascularization - Pipeline Review, H2 2015', provides an overview of the Choroidal Neovascularization's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Choroidal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Choroidal Neovascularization and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Choroidal Neovascularization pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents
 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Choroidal Neovascularization Overview 9
Therapeutics Development 10
Pipeline Products for Choroidal Neovascularization - Overview 10
Pipeline Products for Choroidal Neovascularization - Comparative Analysis 11
Choroidal Neovascularization - Therapeutics under Development by Companies 12
Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes 13
Choroidal Neovascularization - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Choroidal Neovascularization - Products under Development by Companies 17
Choroidal Neovascularization - Products under Investigation by Universities/Institutes 18
Choroidal Neovascularization - Companies Involved in Therapeutics Development 19
Affitech A/S 19
Aprogen, Inc. 20
F. Hoffmann-La Roche Ltd. 21
Genentech, Inc. 22
Iconic Therapeutics, Inc. 23
Mabion SA 24
Navigen Pharmaceuticals, Inc. 25
Noxxon Pharma AG 26
Promedior, Inc. 27
Regeneron Pharmaceuticals, Inc. 28
Sanwa Kagaku Kenkyusho Co., Ltd. 29
Choroidal Neovascularization - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
aflibercept - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antisense Oligonucleotides for Ophthalmology and Cancer - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AP-202 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Doxarubicin Pegylated - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
hI-con1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MAb-30D8 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
NAV-2729 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Netrin-4 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NM-9405 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NOXD-20 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PGN-635 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PRM-167 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ranibizumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ranibizumab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Recombinant Protein for Choroidal Neovascularization - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
RG-7716 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SK-1011 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Choroidal Neovascularization - Recent Pipeline Updates 66
Choroidal Neovascularization - Dormant Projects 82
Choroidal Neovascularization - Discontinued Products 84
Choroidal Neovascularization - Product Development Milestones 85
Featured News & Press Releases 85
Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 85
Mar 11, 2015: Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU 86
Nov 18, 2014: Intravitreal VEGF Inhibitor EYLEA Obtains Additional Indication of Diabetic Macular Edema, Its Fourth Indication 87
Sep 22, 2014: Regeneron Announces EYLEA (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization in Japan 88
Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance 89
Nov 18, 2013: Data at 48 weeks for Phase 3 MYRROR trial in mCNV demonstrate long-term efficacy of VEGF Trap-Eye 89
Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization 90
Jun 06, 2013: Regeneron And Bayer Report Positive Phase III Results For Eylea Injection In Myopic Choroidal Neovascularization 91
May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections 92
Jan 03, 2012: Regeneron Announces Settlement Of Patent Litigation With Genentech For US Ophthalmic Sales Of EYLEA Injection 93
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables

Number of Products under Development for Choroidal Neovascularization, H2 2015 10
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Choroidal Neovascularization - Pipeline by Affitech A/S, H2 2015 19
Choroidal Neovascularization - Pipeline by Aprogen, Inc., H2 2015 20
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 21
Choroidal Neovascularization - Pipeline by Genentech, Inc., H2 2015 22
Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H2 2015 23
Choroidal Neovascularization - Pipeline by Mabion SA, H2 2015 24
Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 25
Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H2 2015 26
Choroidal Neovascularization - Pipeline by Promedior, Inc., H2 2015 27
Choroidal Neovascularization - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 28
Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2015 29
Assessment by Monotherapy Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H2 2015 66
Choroidal Neovascularization - Dormant Projects, H2 2015 82
Choroidal Neovascularization - Dormant Projects (Contd..1), H2 2015 83
Choroidal Neovascularization - Discontinued Products, H2 2015 84